Purinostat Mesylate /m2
Phase 3Small molecule
Purinostat Mesylate /m2 is one of 65 small molecule programs targeting Diffuse Large B-Cell Lymphoma. It is currently in Phase 3.
2
Indications
3
Total Trials
2
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1135 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Ninlaro
TakedaPreclinical
Purinostat Mesylate /m2
CChengdu Zenitar Biomedical Technology Co., Ltd
Phase 3
Prolia
AmgenPreclinical
Eliquis
Bristol-Myers SquibbPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Nolvadex
AstraZenecaPreclinical
Oncovin
EEastern Cooperative Oncology Group
Preclinical
Intron a
Merck & Co.Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Relapsed or Refractory1 trial
Diffuse Large B-Cell Lymphoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Purinostat Mesylate /m2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details